Join the CME/ACPE-accredited 2025 Seattle Cellular Therapy Summit, where leading experts deliver insights on CAR T therapies, lymphoma management, and breakthrough strategies for hematologic malignancies. Register NOW: buff.ly/eJkilhc

Promising: Zanidatamab (a #bispecific HER-2 directed Ab) plus chemotherapy as first-line treatment for patients wit... …rect-com.proxy.library.vanderbilt.edu/science/articl… Jazz Pharmaceuticals The Lancet Oncology #gastric #cancer #cancerresearch Debbie's Dream Foundation: Curing Stomach Cancer

All the best for the match!! You will do amazing things wherever you do. Supriya peshin

🔹FLAURA2 confirms it: Osimertinib + chemo sets a new OS record (50.0 vs 42.1 mo, HR 0.75). But does this kill sequential strategy? Not necessarily. Post-progression Amivantamab still matters perhaps even more after earlier TKI + chemo pressure. 🔗 bit.ly/FLAURA2-OS #EGFR

Journal of Palliative Medicine Danijela Jakovljevic Richa Thakur, MD Rachel Alexander Richard Butin Mulham Ombada, MD Alison Wiesenthal Monika Jain Anna (Annie) LaVigne, MD Paul Nurse, DO, MS Gabrielle Langmann, MD, MS Sonal Admane, MD, MPH Rajiv Agarwal MD Shipra Gandhi Sienna Durbin Côme Bommier Juan E Correa-Morales Gabriel Aleixo Ongoing #video summaries of the #Top10Tips paper for #hpm on #survonc published in Journal of Palliative Medicine Presenting Tip 5⃣ #FinTox 💰💸 Fumiko Ladd Chino, MD, FASCO Yousuf Zafar, MD MHS @Mombada1 Monika Jain Tulsi Jose, MD Dr Snezana Bosnjak Chandrikha Chandrasekharan Gretchen A. McNally PhD MPH 🤩(she/her) Aarsh Desai Ishwaria Subbiah, MD MS FASCO

Dr. Anthony El-Khoueiry ⁦USC Norris Comprehensive Cancer Center⁩ giving an excellent overview regarding combo #IO in #HCC moderated by ⁦Ghassan Abou-Alfa⁩ #cancer #cancerresearch. Great meeting chaired by ⁦Tanios Bekaii-Saab, MD⁩ and ⁦Eileen M O’Reilly⁩ ⁦AHPBA⁩

August 1 marks #WorldLungCancerDay — a time to reflect, raise awareness, and recommit to changing the future of lung cancer. We’ve made meaningful progress, but there’s still a long way to go. Each patient, each study, each step forward brings us closer to better outcomes.

Our recent publication explores the role of concurrent IVIG and platelet transfusion in patients with refractory #alloITP undergoing #alloHCT. Muhammad Umair Mushtaq (Abu Mikael) Nausheen Ahmed MD Muhammad Kashif Amin, MD Al-Ola A Abdallah MD (USMIRC) Moffitt Cancer Center sciencedirect.com/science/articl…

New Pub - Continuous IVIG (2 g/kg) with 48-hr platelet infusion may safely overcome refractory alloimmune thrombocytopenia after allo-HSCT, serving as a bridge until platelet engraftment or for urgent high-bleeding-risk situations. sciencedirect.com/science/articl….

Grateful to be able to contribute to this. Muhammad Umair Mushtaq (Abu Mikael) ASCO PallOnc Community of Practice Dr Joseph McCollom DO Conquer Cancer, the ASCO Foundation H.O.M.E ASH Anurag Singh KU Medical Center Loma Linda University School of Medicine

Check out our recent analysis The Oncologist under mentorship of Aakash Desai, MD, MPH, FASCO of 653 solid tumors evaluating HER2 by IHC, CNV & mutational profiling. 📊 Results: •IHC+: 3+ (3.1%), 2+ (13.2%), 1+ (19.8%), 63.9% neg •CN amplification: 3.1% (75% IHC3+) •Pathogenic ERBB2 mutations: 3.1%

Excited for this analysis of #HER2 alterations/overexpression is now out in The Oncologist! 👇 Hem-Onc Fellows Network LungCancerRx 🫁💊 OncoAlert OncoDaily

A summer 🌞 of firsts. Overjoyed to share my #inaugural editorial with 🥇 peer mentor Mazie Tsang, MD, MAS, MS in JCO Oncology Practice 🤖⏱️ #Wearable tech is transforming #SuppOnc and how we assess patient fitness 🏋️‍♀️ Excellent work to Eva Ruiz Hispán and her colleagues Ravi B. Parikh

🚨 Trial Launch! Excited for my investigator-initiated DISCERN study now LIVE UAB O'Neal Comprehensive Cancer Center! ➡️PD-L1- advanced #NSCLC with ctDNA response to understand dual vs single IO + chemo, a pragmatic trial! IASLC LungCancerRx 🫁💊 Oncology Brothers Clinical Lung Cancer bit.ly/41pf8N2

Hey, don’t forget to submit that #GI26 abstract! It’s your time to shine and help shape the future of GI cancer care with your #gicsm study in progress or a late-stage clinical trial. Abstracts are due Sept. 9 at 11:59 p.m. (ET). Learn more: brnw.ch/21wVvgq

A dream come true: Published in the NEJM as Senior & Corresponding Author! This milestone belongs to my village: my family, my incredible mentors (Dr George) & leaders, and my friends. This one is for you, Doctor Chacha, watching and celebrating from heaven. 🙏 God is good 😇

So so proud of this stellar team at OU Health Stephenson Cancer Center!!! Congratulations Nishant Rajendra Tiwari!!🤩🤩🤩 OU DOM Resident Research OU College of Medicine OU Internal Medicine Residency

🚨Real World Case Video ✅PFS 15.81 mo, ✅DoR 22.1 mo, ✅ORR 40% with osimertinib—uncommon EGFR mutations in lung cancer just got a possible game-changer! Dr. Darren Wijaya’s MOASC 2025 video Poster 👉 oncologytube.com/uncommon-egfr-… Loma Linda U. Health Aakash Desai, MD, MPH, FASCO MOASC The Innovation | Medicine

Today is the day! Ryan Nipp, MD, MPH, MBA, FASCO is one legend you don't want to miss as he summarizes #ASCOQLTY25 for ASCO PallOnc Community of Practice. If you don't have the link, send us a message or get added to the listserv. Danijela Jakovljevic Richa Thakur, MD Rachel Alexander Richard Butin @Mombada1 Alison Wiesenthal

Ummul. Asfeen. DO, MBBS Aoibheann Conneely Raj Shah AmyWebb Simon Noah Etkind Miriam Ní Challaráin 😷 Conor Buckley Kean Yew Liew @JorgeOct @Mombada1 Monika Jain Tulsi Jose, MD Dr Snezana Bosnjak Chandrikha Chandrasekharan Gretchen A. McNally PhD MPH 🤩(she/her) Aarsh Desai Ishwaria Subbiah, MD MS FASCO @Mombada1 Anh Lam (she/her) Abhinav Vyas, MD Ben Thompson